AACR 2019: Diet May Influence Gut Microbiome and Response to Immunotherapy
Among patients with melanoma treated with anti–programmed cell death protein 1 (PD-1) immunotherapy, consumption of a high-fiber diet was associated with higher gut microbiome diversity and better response to treatment, according to data presented by Spencer et al at a presscast in advance of the American Association for Cancer Research (AACR) Annual Meeting 2019 (Abstract 2838 / 24).
“We found that diet and supplements appear to have an effect on a patient’s ability to respond to cancer immunotherapy, most likely due to changes in their gut microbiome,” said first study author Christine Spencer, PhD, research scientist at the Parker Institute for Cancer Immunotherapy, during the presscast. “The gut microbiome plays a big role in moderating the immune system, so the idea that we could potentially change the microbiome—whether by diet or other means—to improve response to immunotherapy treatment is really exciting.”
Spencer and colleagues from The University of Texas MD Anderson Cancer Center previously reported that patients with melanoma who had a diverse gut microbiome enriched in bacteria of the Ruminococcaceae family were more likely to respond to anti–PD-1 treatment. “In our current study, we wanted to look at how diet and supplements affect the microbiome and modulate responses to checkpoint immunotherapy,” Dr. Spencer said.
Study Methods and Findings
Utilizing prospectively collected fecal samples from 113 patients with melanoma starting treatment at the MD Anderson Cancer Center, the researchers characterized the diversity and type of bacterial species found in the gut microbiome. They found that higher microbiome diversity was associated with response to therapy—regardless of treatment type—and that the gut microbiome did not significantly differ based on age, sex, and body mass index.
Among patients who completed baseline dietary surveys, researchers found that eating whole grains, fruits and vegetables, and a high-fiber diet was positively associated with bacteria previously shown to confer response to anti–PD-1 treatment. Diets high in added sugars and processed meat were negatively associated with these bacteria. In a subset of 46 patients treated with anti–PD-1 immunotherapy, the researchers found that patients who consumed a high-fiber diet were about five times as likely to respond to anti–PD-1 treatment compared to patients who consumed a low-fiber diet.
“We know from prior research that eating a higher-fiber diet has a lot of health benefits,” Dr. Spencer said. “But with this preliminary research on patients [with cancer] and the microbiome, it appears that fiber is also linked to a better response to immunotherapy.”
Among all surveyed patients, more than 40% reported use of probiotic supplements, which was associated with lower gut microbiome diversity. Dr. Spencer noted that low gut microbiome diversity has been linked to poorer response to checkpoint inhibitor immunotherapy. Probiotics are not regulated by the U.S. Food and Drug Administration (FDA).
“There’s a perception that taking probiotics improves gut health, but our results, although early, suggest that may not be the case for patients [with cancer],” said Dr. Spencer.
“Based on these preliminary results, we need to reconsider use of over-the-counter probiotics in patients with cancer, at least until we have more data supporting their potential safety and efficacy,” said senior author Jennifer Wargo, MD, MMSc, a Parker Institute investigator at MD Anderson, where she is also Associate Professor of Surgical Oncology and Genomic Medicine.
During the presscast, AACR President Elizabeth Jaffee, MD, commented that this study pointed out “how patients can be empowered to influence their response to our therapies,” and that “the microbiome has importance in probably many cancers”—not just melanoma.
The research group will be presenting additional results at the meeting.
Limitations of the study include a small sample size and a reliance on self-reported diet and supplement use.
Disclosure: This study was sponsored by the Melanoma Research Alliance, the MD Anderson Melanoma Moonshot, the Miriam and Jim Mulva Research Fund, and the Miriam and Sheldon G. Adelson Medical Research Foundation. The study authors' full disclosures can be found at abstractsonline.com.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
